SS1 (dsFv) PE38

Phase 1Small molecule

SS1 (dsFv) PE38 is one of 7 small molecule programs targeting Non-Small Cell Lung Adenocarcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung AdenocarcinomaActive, not recruiting

Non-Small Cell Lung AdenocarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Non-Small Cell Lung Adenocarcinoma

#DrugCompanyPhaseTrials

Tagrisso

Taxotere

1 3

SI-B001

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 4

Taxol

Teva

Phase 1

1 5

Avastin

BBio-Thera Solutions

Phase 1

1 6

Paraplatin

AAvyxa

Phase 1

1 7

SS1 (dsFv) PE38

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Adenocarcinoma1 trial

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01051934·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SS1 (dsFv) PE38. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SS1 (dsFv) PE38 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SS1 (dsFv) PE38. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

SS1 (dsFv) PE38

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News